Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09VDQ
|
|||
| Drug Name |
Pyrimidinone derivative 4
|
|||
| Synonyms |
PMID26118988-Compound-23
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C51H36F6N10O5
|
|||
| Canonical SMILES |
CC1=C(C=C(C(=O)N1C2=CC=CC(=C2)C(F)(F)F)C(=O)NCC(CNC(=O)C3=CC(=C(N(C3=O)C4=CC=CC(=C4)C(F)(F)F)C)C5=CC=NN5C6=CC=C(C=C6)C#N)O)C7=CC=NN7C8=CC=C(C=C8)C#N
|
|||
| InChI |
1S/C51H36F6N10O5/c1-29-40(44-17-19-62-66(44)35-13-9-31(25-58)10-14-35)23-42(48(71)64(29)37-7-3-5-33(21-37)50(52,53)54)46(69)60-27-39(68)28-61-47(70)43-24-41(45-18-20-63-67(45)36-15-11-32(26-59)12-16-36)30(2)65(49(43)72)38-8-4-6-34(22-38)51(55,56)57/h3-24,39,68H,27-28H2,1-2H3,(H,60,69)(H,61,70)
|
|||
| InChIKey |
KYPHYLQIJUHQAO-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neutrophil elastase (NE) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Neutrophil elastase (NE) | Target's Patent Info | [1] | |
| KEGG Pathway | Transcriptional misregulation in cancer | |||
| Systemic lupus erythematosus | ||||
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||
| C-MYB transcription factor network | ||||
| Reactome | Collagen degradation | |||
| Degradation of the extracellular matrix | ||||
| Activation of Matrix Metalloproteinases | ||||
| WikiPathways | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | |||
| Human Complement System | ||||
| Degradation of collagen | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.